An ICER equity analysis calculated that Black Americans, who have a 57.8% hypertension prevalence rate, could see 20% greater benefit from effective blood pressure treatments than the general U.S. population.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Drug pricing policy, insurance prior authorization, and essential drug shortages affecting medication affordability and access.